Molecular Networks Announces Partnership with Thomson Reuters
News Apr 26, 2010
THERESA is a reaction database-driven program system that assists chemists in identifying and developing entirely novel organic synthesis routes for their target compounds. Leveraging Current Chemical Reactions database, which provides the latest synthetic methods reported in over 100 of the world's leading organic chemistry journals including back files to 1986, plus INPI archives from 1840 to 1985, THERESA Prime is a new, powerful tool available for organic and medicinal chemists to address and better solve their challenges in synthesis design more easily and rapidly.
"We are delighted to work with Molecular Networks and to integrate the Current Chemical Reactions database into their innovative THERESA application that offers a new dimension in computer-assisted synthesis design with its intelligent and novel way to design new synthesis pathways based on similarity searching in reaction databases", said Keith MacGregor, executive vice president at the Healthcare & Science business of Thomson Reuters.
Dr. Christof H. Schwab, Director of Marketing and Sales of Molecular Networks, adds, "We highly appreciate and value the integration of the Current Chemical Reactions database, a world-wide recognized source for chemists, to analyze and plan how a certain chemical compound can be synthesized, in THERESA Prime. Customers and users of this combined product will greatly benefit from this partnership in their effort to synthesize new chemical compounds."
The ideal drug is one that only affects the exact cells and neurons it is designed to treat, without unwanted side effects. This concept is especially important when treating the delicate and complex human brain. Now, scientists have revealed a mechanism that could lead to this kind of long-sought specificity for treatments of strokes and seizures.READ MORE